Creo Medical Group Plc logo

Creo Medical Group Plc(LSE) CREO

Market Cap£47.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-87%
5 Year-94%
1 Year-6%
1 Month-15%
£0.10
+1.85%
+0.00Today
Creo Medical Group Plc last closing stock price
MetricPriceDate
Last closeGBX 10.502026-10-15
Creo Medical Group Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.05%GBX 10.502026-10-08
1 month-15.23%GBX 12.382026-09-15
3 month-24.39%GBX 13.882026-07-17
Year to date+6.01%GBX 9.902025-12-31
1 year-5.71%GBX 11.132025-10-15
3 year-69.13%GBX 34.002023-10-16
5 year-93.83%GBX 170.002021-10-15
Since inception-86.86%GBX 0.802016-12-09

Creo Medical Group Plc Financials at a Glance

Market Cap

£47.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£24.40M

Net Income (TTM)

-£14.20M

EPS (TTM)

-£0.05

P/E Ratio

-2.32

Dividend

£0.00

Beta (Volatility)

-0.08 (Low)

Price

£0.10

Volume

549,599

Open

£0.10

Previous Close

£0.10

Daily Range

£0.10 - £0.11

52-Week Range

£0.10 - £0.19

Estimated Earnings Date

Jun 2, 2027

CREO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Creo Medical Group Plc

Creo Medical Limited is a UK-based company specializing in the development of innovative electrosurgical medical devices for surgical endoscopy applications. Founded in 2003, the company is known for its advanced energy platform, Croma, which powers a range of multi-modal instruments designed to enhance therapeutic interventions.

Products and Services
  • Croma: An advanced energy platform for surgical endoscopy
  • Speedboat Inject: A versatile energy instrument for flexible endoscopic procedures
  • MicroBlate Flex: A flexible microwave ablation device for targeted tissue treatment
Growth Outlook
  • Recent quarterly revenue reached £3.2 million, indicating potential for growth
  • Strong product pipeline with innovative devices aimed at improving surgical outcomes
  • Market demand for minimally invasive surgical solutions continues to rise
Financial Highlights
  • Trailing twelve months (TTM) revenue of £15.1 million, reflecting a growing market presence
  • Current ratio of 2.79, indicating strong liquidity position
  • Net income for the latest quarter was -£7.2 million, highlighting ongoing investment in growth
Creo Medical Limited is positioned in the healthcare sector, focusing on medical devices that cater to the evolving needs of surgical professionals. The company's innovative approach to electrosurgery aims to improve patient outcomes through advanced technology. With a robust product portfolio and a commitment to research and development, Creo Medical is well-placed to capitalize on the increasing demand for minimally invasive surgical solutions. The financial metrics indicate a company in a growth phase, with significant investments aimed at expanding its market reach and enhancing product offerings.
AI Generated • Oct 2, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

109

CEO

Craig Jonathan Gulliford

Website

www.creomedical.com

Headquarters

Chepstow, WA NP16 5UH, GB

CREO Financials

Key Financial Metrics (TTM)

Gross Margin

28.57%

Operating Margin

-267.14%

Net Income Margin

-268.57%

Return on Equity

-38.29%

Return on Capital

-38.26%

Return on Assets

-33.10%

Earnings Yield

-43.10%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£47.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

449.14M

Volume

549.60K

Avg. Volume

739.61K

Financials (TTM)

Gross Profit

£10.20M

Operating Income

-£42.40M

EBITDA

-£39.10M

Operating Cash Flow

-£28.30M

Capital Expenditure

£0.00

Free Cash Flow

-£28.30M

Cash & ST Invst.

£7.40M

Total Debt

£3.90M

Creo Medical Group Plc Performance Analysis

Creo Medical Group Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 27,169,0008.0%
20232023-12-31GBP 4,000,000-85.3%
20242024-12-31GBP 4,000,0000.0%
20252025-12-31GBP 6,000,00050.0%
Creo Medical Group Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-3172.7%
Q22026-06-30-15.8%
Creo Medical Group Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP -0.14-0.6%
20232023-12-31GBP -0.07-51.7%
20242024-12-31GBP -0.0812.0%
20252025-12-31GBP 0.01N/A
Creo Medical Group Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-31-169.0%
Q22026-06-3038.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

£3.20M

-78.8%

Gross Profit

£1.10M

-85.9%

Gross Margin

34.38%

N/A

Market Cap

£47.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£453.46K

N/A

Employees

104

N/A

Net Income

-£7.20M

+28.7%

EBITDA

-£7.60M

+18.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

£7.40M

-24.5%

Total Debt

£3.90M

-72.5%

Accounts Receivable

£10.80M

+9.1%

Inventory

£1.90M

-77.6%

Long Term Debt

£800.00K

-92.5%

Short Term Debt

£3.10M

-11.4%

Return on Assets

-33.10%

N/A

Return on Invested Capital

-38.16%

N/A

Free Cash Flow

-£9.40M

+33.8%

Operating Cash Flow

-£9.40M

+31.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HEMO.LHemogenyx Pharmaceuticals Plc
£6.14-13.52%
HVO.LhVIVO plc
£0.06+0.00%
NCYT.LNovacyt S.A.
£0.40+2.59%
KOO.LKooth plc
£1.87+0.81%

Trending Stocks

Symbol / CompanyPricePrice Chg
CCCCCC Intelligent Solutions
$7.63-0.13%
INTCIntel
$95.37-2.80%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$107.35-2.89%
CRWVCoreWeave
$69.69+5.94%

Questions About CREO

What is the current price of Creo Medical Group Plc?

Creo Medical Group Plc is trading at £0.10 per share.

What is the 52-week range for Creo Medical Group Plc?

Over the past 52 weeks, Creo Medical Group Plc has traded between £0.10 and £0.19.

How much debt does Creo Medical Group Plc have?

As of the most recent reporting period, Creo Medical Group Plc reported total debt of £4.10M.

How much cash does Creo Medical Group Plc have on hand?

Creo Medical Group Plc reported £12.40M in cash and cash equivalents in its most recent financial results.

What is Creo Medical Group Plc’s dividend yield?

Creo Medical Group Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services